| 2025 | 2024 | 2023 | 2022 | 2021 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 206,8 k € | +25.2% | 165,2 k € | +260.3% | 45,9 k € | +503.7% | 7,6 k € | -55.8% | 17,2 k € | -37.6% | 27,5 k € | +4.1% | 26,4 k € | -3.2% | 27,3 k € | -34.4% | 41,7 k € | -32.9% | 62,0 k € | +79.7% | 34,5 k € | -28.0% | 47,9 k € | -13.6% | 55,5 k € | +139.3% | 23,2 k € | |
| EBITDA | 203,7 k € | +25.6% | 162,2 k € | +273.2% | 43,4 k € | +674.7% | 5,6 k € | -63.1% | 15,2 k € | -40.2% | 25,4 k € | +4.5% | 24,3 k € | -3.1% | 25,1 k € | -37.4% | 40,1 k € | -34.0% | 60,7 k € | +83.7% | 33,1 k € | -25.0% | 44,1 k € | -18.2% | 53,9 k € | +145.6% | 22,0 k € | |
| Operating profit | 197,1 k € | +29.9% | 151,8 k € | +272.0% | 40,8 k € | +700.8% | 5,1 k € | -64.3% | 14,3 k € | -38.8% | 23,4 k € | +4.9% | 22,3 k € | +3.5% | 21,5 k € | -13.3% | 24,8 k € | -42.7% | 43,3 k € | +161.4% | 16,6 k € | -39.0% | 27,2 k € | -26.5% | 37,0 k € | +114.7% | 17,2 k € | |
| Profit/loss | 130,2 k € | +23.6% | 105,4 k € | +299.7% | 26,4 k € | +7087.0% | 366,8 € | -94.6% | 6,8 k € | -48.9% | 13,4 k € | -11.9% | 15,2 k € | +2.0% | 14,9 k € | -26.6% | 20,3 k € | -45.8% | 37,4 k € | +172.6% | 13,7 k € | -38.0% | 22,1 k € | -21.1% | 28,0 k € | +118.6% | 12,8 k € | |
| Equity | 285,0 k € | +76.9% | 161,1 k € | +189.1% | 55,7 k € | -6.4% | 59,5 k € | -44.3% | 106,9 k € | +12.6% | 94,9 k € | +15.3% | 82,3 k € | +5.8% | 77,8 k € | +6.7% | 72,9 k € | +7.8% | 67,6 k € | +12.2% | 60,3 k € | +6.6% | 56,5 k € | +14.4% | 49,4 k € | +57.4% | 31,4 k € | |
| Total assets | 360,7 k € | +75.7% | 205,3 k € | +128.1% | 90,0 k € | +24.2% | 72,5 k € | -44.6% | 130,8 k € | -9.0% | 143,8 k € | +9.5% | 131,3 k € | +8.2% | 121,4 k € | -3.0% | 125,2 k € | -7.3% | 135,1 k € | +21.8% | 110,9 k € | -18.9% | 136,7 k € | -7.1% | 147,1 k € | +47.1% | 100,0 k € | |
| Cash | 278,6 k € | +86.1% | 149,7 k € | +205.7% | 49,0 k € | +31.6% | 37,2 k € | -67.9% | 115,7 k € | -9.8% | 128,4 k € | +17.5% | 109,2 k € | +23.7% | 88,3 k € | -16.7% | 106,0 k € | +4.7% | 101,2 k € | +85.1% | 54,7 k € | -27.6% | 75,6 k € | +8.1% | 69,9 k € | +1.7% | 68,7 k € | |
| Debts | 74,3 k € | +79.1% | 41,5 k € | +22.1% | 34,0 k € | +169.0% | 12,6 k € | -45.9% | 23,3 k € | -52.3% | 48,9 k € | -0.2% | 49,0 k € | +12.3% | 43,6 k € | -16.6% | 52,3 k € | -22.4% | 67,5 k € | +33.3% | 50,6 k € | -36.8% | 80,1 k € | -18.0% | 97,6 k € | +42.3% | 68,6 k € | |
Private limited company · Destelbergen · incorporated on 30/01/2009
Private limited company profitable and well capitalised. Cash position rising (+86.1%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Asclepia MedChem Solutions is a Private limited company incorporated in 2009. Its main activity is: Manufacture of basic pharmaceutical products. Its registered office is in Destelbergen.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.